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Cancer Services Report
Regional

William j. Laffey, MBA

Director

Most of you who will read this annual report live in Wisconsin. So, why
be concerned about melanoma? Isn’t it mostly caused by exposure to the

Cancer Services
Regional Director

sun? Most cities in the state average only 54% sunny days per year, a long
way from Phoenix at 85%! Does that mean we are less susceptible to this
disease? And isn’t melanoma rare, anyway? Why be concerned?

Well, here are a few good reasons. Cancer of the skin is the most common
of all cancers. Although melanoma accounts for only about 4% of all skin
cancers, it causes about 79% of skin cancer deaths, primarily because,
unlike other skin cancers, it frequently metastasizes. In some parts of the
world, especially among Western countries, the number of people who
develop melanoma is increasing faster than any other cancer. In the United
States, the number of new cases of melanoma has more than doubled in
the past 20 years.

The good news is the variety of ways to lower the risk of melanoma. Even
with lack of sunshine in Wisconsin, ultraviolet light can still come through
on hazy days or days with light or broken cloud cover. Appropriate
clothing, sunscreen, sunglasses and avoiding the use of tanning beds
and sunlamps can go a long way toward prevention.

Within the pages of this report, you’ll

An important part of our cancer program

hear from cancer experts who will discuss

is education, both to patients and providers.

screening, detection, prevention, education,

We trust that the provider reading this report

treatment and even genetic predisposition for

will find something that assists them either in

melanoma. From screening clinics to research

caring for their patients or providing a referral.

trials to vaccine therapy and beyond, the

We also trust that our annual report gives

oncology program at Aurora Health Care

the patient or family member reading it

is a leader in science, technology and

something equally important

compassionate patient care.

believing that a team of experts at Aurora

—

a reason for

is dedicating their professional lives to the
prevention, diagnosis and treatment of cancer,
whether it be melanoma or any other form
of this disease.

St. Luke’s Medical Center
Chairman’s Report

Over the past year the cancer committee has been involved in many
exciting projects. The 3rd annual Men’s Health Conference was recently
Cancer Committee
Chairman

held at Mayfair Mall. Lectures and information for different men’s health
issues were provided. Also, on September 2nd, 5th and 6th the National
Prostate Cancer Coalition mobile screening vehicle offered free prostate
screening with PSA testing to the participants at the Church of God in
Christ (COGIC) conference at the Hyatt in Downtown Milwaukee. These
programs were a great success. A special thanks to the physicians who
participated and also to Marija Weidman who orchestrated these events.
Again this year the Buddies Against Prostate Cancer, Bob Reitman, Gary
Grunau and Ken Sanders sponsored the annual Buddies Against Prostate
Cancer golf outing The monies raised by the event help support the Men’s
Health Conference and prostate cancer awareness. I would like to thank
them personally and everyone involved who helped make this year’s events
so successful.

St. Luke’s Medical Center continues to be at the forefront of advanced
technology in the treatment of cancer. Intensive Modulated Radiation
Therapy (IMRT) now available at St. Luke’s Medical Center is typically
used in treating previously radiated cancers and in treating the primary
tumors that are in close proximity of delicate organs such as the eyes
and spinal cord.

IMRT is also utilized to treat primary metastatic

The community outreach activities that have

brain tumors, pancreatic tumors, liver tumors,

taken place throughout the year can be found

prostate cancer, head, neck and lung cancer.

in the annual report. The Vince Lombardi Ball

Radiofrequency interstitial tissue ablation of

and Golf Classic this year was another great

painful bony metastasis also is now available

success. Hank Aaron was named the official

at St. Luke’s Medical Center. St. Luke’s Medical

honoree. I would like to personally thank

Center also is looking to become a prostate

Patty Abella and the many volunteers who

vaccine trial site in the near future. St. Luke’s

have made this event a tremendous success.

performed its 200th Gamma Knife procedure

The “Race for the Cure” will be held again

at the end of last year. Robotic surgery is now

this fall. The 5K run and walk raises money

being performed at St. Luke’s Medical Center.

to be used for community-based breast health

The new surgical technology has been used in

education, cancer screening and treatment

the treatment of thoracic cancer, abdominal

options for medically underserved individuals.

and even genitourinary malignancies.
Finally, I would like to personally thank the
members of the cancer committee for their
hard work and dedication throughout the
year. They have made the Cancer Services
Program at St. Luke’s and throughout the
greater Metro area second to none.

I’
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Aurora Sinai Medical Center
Chairman’s Report

William L. Donegan,

The struggle against cancer is like the Chinese story of the old man who
moved a mountain. It seems a small town was blocked from the nearby

MD, FACS
Cancer Committee

shore by a large mountain, and the mountain had always cast a gloomy
shadow on the town. One day an old man who lived in the town picked
up a shovel and walked up onto the mountain and began to dig. Some

Chairman
people nearby saw him, climbed up to him and asked what he was doing.
He said, “I am moving this mountain.” They all laughed. “Old man,” they
said, “you must be senile. You can’t move this mountain. You are alone,
and you have only a shovel.” The old man said, “That is true. But I will
dig every day, and my family and friends will come and help. When others
see what a good thing it would be to move this mountain, they will also
come and dig. After us, our children will dig, and eventually the mountain
will be moved.”

Cancer is like the mountain; daunting, overwhelming in its magnitude, but
multitudes are digging away each day to move this mountain. The shovels
are busy at Aurora Sinai Medical Center.

The Medical Oncology Clinic became a Vince Lombardi Cancer Clinic
(VLCC) this year, joining the network of VLCC’s at other Aurora Metro
area institutions. The Vince Lombardi name associates the clinic with
this famous personality and appropriately with his indomitable spirit.

At the clinic, a study of patient expectations

Profile System (FIPS). We continue to

regarding side effects of chemotherapy and

participate in randomized trials of cancer

goals of treatment was presented as a poster

treatment and prevention through national

at the annual meeting of the American Society

cooperative groups. Medicine is increasingly

of Clinical Oncology.

evidence based, and progress is dependent
on these trials to provide secure evidence for

The cancer registry prepared to implement

the efficacy of potentially useful practices.

the newest version of the TNM cancer staging

The Missouri slogan, “You gotta show me,”

system that was published by the American

comes to mind. Trials often require years of

Joint Committee on Cancer this year, and

patient-sustained effort to complete, and

that will be required in approved cancer

provision for continuity is important. For

programs beginning in January 2003. The

example, the SELECT trial which tests whether

TNM system originated in the 1940s and is

supplemental selenium and vitamin E can

used internationally to categorize cancers of

prevent prostate cancer in healthy men

all types. A uniform staging system enables

will require more than 32,000 participants

physicians to speak a common language

nationwide and will continue until 201 3. It is

when communicating about cancer. Staging

anticipated that the STAR trial of breast cancer

establishes prognosis, guides treatment

prevention with tamoxifen or raloxifene will

decisions and helps compare treatment

require five more years to complete.

outcomes. Our tumor registrars carefully

-z:•

record the stage for each patient, ensure its

In 2001, the new bi-weekly breast disease

accuracy and provide this to the National

consultation conference became a reality

Cancer Data Ease and for studies when

at Aurora Sinai Medical Center. This

needed. At Aurora Sinai Medical Center,

multidisciplinary,’working conference

registrars also organize the weekly tumor

focuses on patients with breast cancer, our

conference and make sure that staging

most frequent malignancy. The informal

information is included among the materials.

interchange between physicians, nurses

Aurora Sinai Medical Center is among the

and other health professionals regarding

54% of approved cancer programs that share

newly-diagnosed cases is intended to

staging information with the American Cancer

promote optimal patient care.

Society through the Facility Information

Meanwhile, the regular institutional tumor

If approved, this change will consolidate

conference met 48 times during the year

our cancer programs, integrating our tumor

with an average attendance of 37. A survey

registries and many of our services.

of attendees indicated a 98% approval rate.
This year’s annual report is on melanoma, the
Among other community services, we

most dangerous cancer of the skin. Melanoma

supported “Race for the Cure”, the

is promoted by sun exposure, so perhaps it

Southeastern Wisconsin Cancer Conference,

comes as no surprise that Milwaukee has one

and the annual Men’s Health Conference.

of the lowest frequencies of melanoma in the

The Breast Health Center concentrated on

country. Fortunately, measures can be taken

expediting communication with patients

to prevent melanoma, and, as described in

regarding diagnostic results. We heard

this report, by staying alert for its typical signs,

from the Radiology Department about

melanoma can be effectively managed with

the prospects of a program for chemo

early detection and treatment.

embolization and for radiofrequency ablation
of tumors. Patient care evaluation studies

It was a pleasure to chair the Cancer

were performed on brain and liver cancers

Committee this year. My thanks to the

and the registry contributed pathology data

administration for continued support of the

on ductal carcinoma in situ of the breast to

cancer program, to the members of the

the Commission on Cancer. Radiation therapy

Cancer Committee, to our cancer registrars,

services at Aurora Sinai Medical Center

to those who keep our institution at the

switched from afternoon to morning hours

forefront of cancer prevention, diagnosis

for greater patient convenience.

and treatment and to all who in so many
ways continue to dig away at the mountain.

In 2002, Aurora Sinai Medical Center is
applying together with St. Luke’s Medical
Center and West Allis Memorial Hospital for
accreditation as a Network Cancer program.

H

H
-

West Allis Memorial Hospital
Chairman’s Report

-I

Rakesh Jagetia, MD

The Oncology program at West Allis Memorial Hospital has remained
very successful in continuing to provide the highest quality of care to our

Cancer Committee
Chairman

patients. Many changes have occurred at West Allis Memorial Hospital
over the past year. The much-anticipated opening of the Aurora Women’s
Pavilion this spring was very well received by the community. By integrating
many services at a single location, we are able to provide a unique element
of convenience, comfort and quality to the patients and their families.
Not only are there many educational programs and classes, but also, pain
management, various fitness programs, psychological support, genetic
counseling, complementary medicine and other such programs are
provided to the patients, families and the community. We continue to
view end-of-life care and palliative care as priorities of the oncology team.
In addition, we continue to strive for excellence in the detection, treatment
and prevention of cancer.

One of the many changes has been the relocation of the Radiation
Oncology Department to the new Aurora Women’s Pavilion. State-of-theart linear accelerators and simulators have been installed. Thus, consistent
with the astounding rate of technological advancement within the oncologic
arena, patients now have access to the latest modalities of treatment,
such as 3-D conformal radiation and prostate brachytherapy.

10

Our patients have available to them the broad

The Annual Report this year is focusing on

range of oncologic services provided with the

Melanoma. Much research and time is being

Metro region, including IMRT

devoted to the treatment of this disease.

—

Intensity

Modulated Radiation Therapy, Coronary

As is clearly evident, the oncologic team has

Intravascular Brachytherapy, Gliasite and

the latest in treatment in chemotherapeutic,

various research protocols. We participate

biologic and radiotherapeutic options within

in most national intergroup trials, sponsored

its arsenal to help treat such a potentially

by RTOG, ECOG and other such national

devastating disease.

cooperative groups. An exciting area of
growth in breast cancer has been the FDA

It again has been a pleasure and a privilege

approval of the Mammosite device for breast

to chair the Cancer Committee at West Allis

brachytherapy. This allows us to deliver

Memorial Hospital. We have increased

radiation therapy using a high dose rate unit

membership to have representation from

over the course of 5 days.

other disciplines. I would like to thank each
of the existing and new cancer committee

The Cancer Committee members and staff

members for your participation. Because

of West Allis Memorial Hospital remain active

of your efforts and contributions, we have

from the education perspective of cancer care.

developed an excellent cancer program

With weekly Tumor Boards, a multidisciplinary

at West Allis Memorial Hospital and the

team prospectively discusses a variety of

Metro Region.

cancer cases. An additional Tumor Board
devoted entirely to prospective breast cancer
cases is in the process of starting. Also,
with the aid of videoconferencing, we have
conducted joint Tumor Boards with our
colleagues in Green Bay. Members continue
to actively participate in Grand Rounds
seminars, and lecture series as well as
volunteer at community events.

L1J__

Aurora Medical Center
in Hartford
Chairman’s Report

Jonathan Treisman, MD

Positive progress and change occurred with the oncology program in
Hartford over the course of the last year. The hospital underwent a name

Cancer Committee
Chairman

change from Hartford Memorial Hospital to Aurora Medical Center in
Hartford. This name change enhances awareness of the multitude of
programs and resources that are made available to the public by Aurora
Health Care throughout eastern Wisconsin. In oncology, such things
include participation in clinical trials, support groups, educational activities
and state-of-the-art diagnostic and therapeutic technologies.

It is the intent of Aurora to provide any service, at any location, to any
patient, at any point in their continuum of care. For example, this year’s
annual report focuses on malignant melanoma. Within the network of
Aurora Health Care, a patient diagnosed with malignant melanoma could
have their excision done in Hartford, their radiation in West Bend, enroll in
the exciting multi-institutional studies involving interluekin, interferon and!
or biochemotherapy, for those with metastatic melanoma in Milwaukee
and still be able to attend support groups close to their home. For more
information on Malignant Melanoma, please review the in-depth study
in this year’s report.

One service that was expanded at Aurora

Hartford/Slinger “Relay for Life” and the

Medical Center in Hartford was the Breast

Annual Bob Cross Memorial Run in West

Health Clinic. The Breast Health Clinic has

Bend. Members of the Cancer Services team

expanded its hours for patients to be seen

also participated in educational radio and

in a multidisciplinary setting in conjunction

print promotions for the public. In terms

with highly-skilled radiology technicians,

of quality control activities, the committee

a radiologist, a personalized breast care

actively reviewed abstracted cancer data

specialist and a surgeon, if necessary. All

for accuracy and completeness and voted

breast care including diagnostic work—up

to participate in the American College

and treatment is coordinated for the patients.

of Surgeon’s recommended patient care
evaluation study on non-small cell lung

Representation from Radiation Oncology

cancer. In addition, a quality control initiative

was made possible for Cancer Committees

was developed to effectively design a better

and Tumor Boards through the use of

work flow procedure and schedule for mixing

videoconferencing technology and the

chemotherapy agents for the hospital as

switching of meeting days from Friday

well as the Vince Lombardi Cancer Clinic.

to Tuesday. The idea of having real-time
webcasting of tumor boards is still being

In conclusion, the cancer program in

explored to facilitate the attendance

Washington County has made huge strides

of providers from outlying clinics and

against cancer. I would like to thank the

offices and to decrease travel time for

members of the cancer committee for their

conference attendees.

time and participation and look forward to
chairing the committee in the coming years.

The cancer committee actively took part
in public education activities such as
the American Cancer Society (ACS)
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Aurora Health Care
Regional Cancer
Registry Report

Lisa Robinson, RHIA, CTR

THREE THOUSAND FOUR HUNDRED AND FORTY TWO is the amount of
new cancer cases the Cancer Registries in the Metro Region accessioned

Regional Manager
Clinical Information

in 2001. St. Luke’s Medical Center including St. Luke’s South Shore saw
2,268, Aurora Sinai Medical Center saw 361, West Allis Memorial Hospital
had 691 and Aurora Medical Center in Hartford saw 122 new cancer

Services

cases. This is over a 9% increase in the amount of cases from the prior year
(2000) and 14% from 1 999. Of the 23,920 newly diagnosed cancer cases
in 1 999 among Wisconsin residents, Aurora Health Care’s analytic case
load constituted 14.3% of those cases, thus reflecting a high degree of
confidence and trust from the general population in regards to the care
Aurora Health Care provides.

A major accomplishment of the registry over the last year was the conversion
of four separate and disparate hospital cancer registry databanks into
one multi-hospital networked system. This system enables the registry to
combine data and follow-up on like patients, thus decreasing duplicate
effort. The ability to combine individual hospital data for reporting purposes
has also fulfilled the American College of Surgeons standard for a combined
registry enabling the Metro region to apply for Networked Accreditation
status through the Commission on Cancer. Currently, St. Luke’s Medical
Center, Aurora Sinai Medical Center and West Allis Memorial Hospital retain

14

full accreditation status as single entities and

The Clinical Data Registrars should be

will be undergoing Network evaluation for

congratulated on their superior involvement,

oncologic corn petencies this winter. At the

coordination and implementation of the

present time, eight Aurora Hospitals in all are

tumor boards and breast conferences that

linked to the Electronic Registry System (ERS)

are set up on a weekly and monthly basis.

and collect a full range of data elements on

Please reference the Cancer Conference

each malignancy diagnosed and or treated

report for more information.

within the facilities. This data contains
information on demographics, cancer

Other educational activities the registrars

work-up, diagnosis and staging, treatment

participated in during 2001 were the

(first course as well as subsequent) and

Wisconsin Cancer Registrar’s Annual Meeting,

remission and recurrence information. The

the 34th Annual Southeastern Wisconsin

future goal is to expand the collection

Cancer Conference on Advances in Lung

of registry data for both the South Region

Cancer, and the 27th Annual National

and North Regions using this software.

Cancer Registrars Association Meeting
in Orlando, Florida.

In addition to hospital reporting, the registry
is also responsible for reporting cancer cases

All Metro Hospitals were successful in

for the larger clinics in the Metro Region,

following more than 90% of all cases in

including Aurora Medical Centers, Wilkinson,

the registry and were well within reporting

Waukesha, Hartford, Hustisford, Slinger, West

limits to the State of Wisconsin and the

Bend, Port Washington and Belgium, and the

National Cancer Data Base (NCDB). Patient

associated Vince Lombardi Cancer Clinics.

Care Evaluations (PCE) completed in 2001

The registry will be beta testing a new

included the gastric and non-small cell lung

reporting software called “Express Reporter”

cancer studies. The registry also satisfied

provided by the State that will enable

over 40 requests for data within the region.

electronic reporting rather than reporting
and submitting of clinic cases on paper.

Data requests can be made through
the Regional Clinical Data Registry office
at (414) 649-7290.
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Role of Radiation in
Melanoma

Perry Gould, MD

Patients

The incidence of cutaneous melanoma has increased significantly during
the past decade with the exact etiology of this increase remaining largely

Radiation Oncology, S.C.

unknown. Fortunately, most of these newly-diagnosed patients are able
to undergo a curative surgery. In those patients who have a more aggressive
disease, who are at risk for future disease spread, treatment advancements
have also occurred to help improve their systemic and regional control.
We even have options to help improve the quality of life in people with
metastatic cancer.

Although the mainstays of melanoma therapy have historically been
surgery, chemotherapy and immunotherapy, radiation is an important
regional and palliative treatment option. The MD Anderson Cancer Center
has reported two important studies assessing the role of radiation in
controlling cervical and axillary lymphatic disease in patients at high risk
for regional failure. The first trial assessed giving 5 fractions of radiation
directed at the cervical lymph node chain in patients with greater than
a 50% risk of lymphatic failure. This trial included patients who had head
and neck melanoma with invasion >1 .5mm, positive lymph node disease
after a limited neck dissection, or a neck dissection after nodal relapse.
The trial showed an improvement in regional control at 5 years of 88%.
Because of the surprisingly positive results of the above study, the same
radiation fractionation scheme was applied to patients with a 50% risk

of axillary failure. They included patients with

There also are several radiation options in

4 lymph nodes positive on axillary dissection,

the management of metastatic melanoma to

a positive lymph node 3cm, extracapsular

the brain. In patients with 1 to 3 brain lesions,

extension or recurrent disease. Again, the

good performance status, and controlled

study showed improved axillary control

systemic disease, gamma knife irradiation

with a 5 year regional control rate of 87%.

is an option. This is a dedicated radiation

In both these studies, the 5 year overall

therapy device which utilizes the radioisotope

survival rate was 50%. These studies

cobalt to deliver a highly conformal dose of

showed radiation has a role in helping

irradiation around the target while minimizing

to control the potentially debilitating

exposure to adjacent normal intracranial

affects of regional metastatic spread.

tissue. In other patients with less favorable
characteristics, external beam therapy is the

Additionally, radiation therapy plays a role

standard of care.

in providing palliative therapy. In the past,
many oncologists thought melanoma was

In conclusion, a variety of treatment options

a radioresistant cancer requiring large

are available for patients with a diagnosis of

doses per fraction to achieve a response.

melanoma. Because of this, a multidisciplinary

A landmark trial by the RTOG showed that

approach is often required. The completion

60% of patients achieve a palliative response

of a number of trials has now shown radiation

regardless of whether large or conventional

therapy to play an important role in the

fractions are given. Although this response

management of regional and metastatic disease.

rate is much lower than with most malignancies,
it is considerably higher than what was
previously assumed. Therefore, there is a
role for palliative external beam irradiation
in patients with soft tissue or osseous disease.
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Ann V. LeFever, PhD
Immunotherapy Program

Immunotherapy for cancers is based on the principle that the patient’s
immune system is capable of generating immune responses against tumor
cells. Currently available treatments for patients with metastatic melanoma

St. Luke’s Medical Center

have been limited by poor response rates and unacceptably low long-term
survival. Melanomas are some of the most immunogenic tumors and thus
are a good model to evaluate the effectiveness of immune-based therapies.

Generation of an effective anti-tumor immune response requires a
complex set of events involving both humoral (antibody) and cell-mediated
interactions. A variety of strategies have been used to enhance immune
responsiveness against melanoma. The cytokine interleukin-2 (lL-2) has
been shown to have activity against melanoma. IL-2 acts by amplifying
John P. Hanson, jr, MD
Medical Director

the anti-tumor cellular immune response. High-dose IL-2 therapy can
result in durable responses in some patients. However, the dose-related
toxicity of high-dose IL-2 therapy requires expert care management and

Immunotherapy Program

multidisciplinary care coordination. The Immunotherapy Program at

St. Luke’s Medical Center

St. Luke’s Medical Center participated in the early IL-2 clinical trials in
the late 1980’s in a collaborative arrangement with the National Cancer
Institute and this experience has enabled us to provide this therapy
to our patients with metastatic melanoma over the past 1 5 years.

I
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Another cytokine with demonstrated activity

While increased clinical responsiveness has

against melanoma is interferon-alpha ((EN-a).

been observed in some clinical trials, the goal

This cytokine has antiproliferative activity and

of achieving durable responses in patients

can modulate the expression of MHC Class I

with metastatic disease has been elusive.

and Class II cell surface molecules on tumor

New innovative approaches and more

cells making the tumor more susceptible

effective therapies for melanoma are needed

to recognition and destruction by the

and one approach that holds promise is

immune system. (EN-a is FDA-approved

immunotherapy with cancer vaccines.

for the adjuvant treatment of patients at

Cancer vaccines rely on the patient’s immune

high-risk of developing metastatic disease;

system to recognize tumors and generate and

however, its use as a single-agent against

effective anti-tumor response. This approach

metastatic disease has been disappointing.

is especially exciting for the treatment of
melanoma since they are among the most

During the past twenty years, clinical

immunogenic tumors. Important developments

trials have been conducted evaluating the

in melanoma vaccines in current years include:

effectiveness of IL-2 and lEN-a combined

1) an understanding of antigen presentation

with non-specific cellular therapies such as

and the role of T-ceIl activation in generating

lymphokine-activated killer ([AK) cells and

an anti-tumor response; 2) the identification

tumor-infiltrating lymphocytes (TIL). While

of melanoma-specific tumor antigens; and 3)

these trials demonstrated activity against

the discovery of T-cells that recognize specific

melanoma, the clinical outcomes were not

peptide fragments that are expressed on the

significantly improved compared to treatment

surface of tumor cells.

with high-dose IL-2 alone. In an effort to

20

improve upon the modest results achieved

Currently, a variety of different types of

with chemotherapy, IL-2 and lEN-a have been

melanoma vaccines are being evaluated in

added to chemotherapy regimens and the

clinical trials. The Immunotherapy Program

treatment is referred to as biochemotherapy.

is participating in a National Cancer Institute

sponsored phase Ill clinical trial using a

Research within the coming years will clarify

highly immunogenic melanoma peptide

the roles of combination chemotherapy

vaccine. The clinical efficacy of this

and immunologic agents which will result

approach wifl be determined in this trial

in more effective treatment strategies

but previous studies with this vaccine

for patients with metastatic melanoma.

demonstrated the generation of anti-tumor

Cancer Services at St. Luke’s Medical

immune responses and the ability to

Center is positioned to provide the latest

generate clinical responses. The future

innovative treatments to our patients

of melanoma vaccines is promising but

with metastatic melanoma.

questions about the route of administration,
the timing of administration and the
effectiveness of combining vaccines
with other agents will be critical in the
development of successful melanoma
cancer vaccines.
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Biochemotherapy
in the Treatment of
Malignant Melanoma

Barbara Ritter,

Melanoma is an increasingly common clinical problem. Over the last three
decades, the incidence of melanoma has been on a steady increase rising

BSN, RN, OCN

at a rate of 4% to 6% per year. Melanoma affects more than 40,000
people nationally with nearly 1 0,000 deaths annually. Currently it is
estimated that one in every 75 people will be diagnosed with melanoma
compared to 1 in 1,500 in 1935. Often this disease affects people in
the prime of their lives with the median age being 45 years. The median
survival of patients with metastatic melanoma is 6 to 9 months with a
5 year survival rate of less than 5%. Effective treatments are necessary
for patients with melanoma.

Carla Rohloff,
Melanoma is one of the few cancers that have been shown to be responsive
BSN, RN, OCN

to biological agents. This has led to various clinical trials involving the
use of immunotherapy based treatments for this disease. Two biologicals,
interferon and interleukin-2 (IL-2) have played an important role in the
treatment of melanoma.

lnterleukin-2 is a naturally occurring protein in the human body that
is critical to activating the immune system. The Food and Drug
Administration (FDA) has approved interleukin-2 (Proleukin) for
metastatic renal cancer and for metastatic melanoma.
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lnterleukin-2 activates the immune system in

Substantial toxicity requiring the expertise

multiple ways. While it does not have direct

of the physician and nurses is associated

cytotoxic effect on cancer cells, it possesses

with the high dose standard dosing. Thus,

the ability to activate natural killer cells

lL-2 therapy is restricted to a select patient

and cytotoxic T lymphocytes to recognize

population and is available in only a few

and destroy melanoma. lL-2 can evoke an

established centers. St. Luke’s Medical Center

immune response to eradicate tumor and

has been offering this therapy for over a

produce long lasting remissions.

decade. The major toxicities associated with
high dose IL-2 therapy include hypotension,

lnterleukin-2 can be administered by several

capillary leak syndrome, cardiac arrhythmias,

routes including intravenous, subcutaneous

gastrointestinal toxicity, fever and chills. Efforts

injections and inhaled or aerosol. The FDA-

in prevention and management of toxicity

approved dose and route of administration is

over the past several years has greatly reduced

600,000 lU/kg intravenously every eight hours

the toxic side effects and provided a beneficial

up to 14 doses per cycle of a two-cycle course

therapy for melanoma.

of treatment. This dose regimen is referred to
as high dose interleukin-2.

Alpha interferon (IFN, lntron-A) is the
first therapy in the adjuvant setting to

One of the largest IL-2 studies evaluating

significantly impact the relapse rate of

270 patients, demonstrated that a complete

patients with melanoma with high risk

response rate of 6% and a 1 0% partial

disease. The name “interferon” was given

response rate was achieved. It is of note

to this immunomodulator for its ability

that many of the patients who responded

to “interfere” with cell replication. Its

remained progression free at a median

antiproliferative actions slow cell division,

follow-up of 62 months. While the percent

primarily in malignant cells, at all stages

of response is low, the duration of this

of the cell cycle. Much like lL-2, interferon

response is impressive.

has profound modulatory actions, most
of which result in activation or alteration
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of natural killer and cytotoxic T-cells.

research has demonstrated that melanoma

Single-agent interferon has a response rate

is one of the few cancers that respond to

of 15% and complete remission rates of

immunotherapy. Response rates ot 15% to

3% to 5% in advanced disease. However,

20% have been observed in patients treated

interferon added to combinations of

with interleukin-2 (IL-2) and interferon (IFN).

chemotherapy agents and other biologicals

More than a decade of clinical trials has

like IL-2, has improved response rates and

shown that promising results can be achieved

demonstrated increased survival benefit.

with treatments that combine standard
chemotherapeutic agents and biotherapy.

Interferon in the oncology setting can be

These combination regimens are referred

administered intravenously or subcutaneously.

to as biochemotherapy. The hope was to

The FDA-approved dose for intravenous route

improve response rates and durable remissions

is 20 million IU/m2 and 10 million IU/m2

in patients with metastatic melanoma.

as per subcutaneous route.
Initially the biochemotherapy regimens were
Especially in combination with other agents,

given sequentially, meaning chemotherapy

interferon toxicity is significant. Physicians

followed by biologic response modifiers. It

and nurses play a major role in side effect

was thought that administering all the drugs

management, which contributes significantly

at the same time would be too toxic. Typically

to the patient’s benefit from therapy. Nursing

the drugs used in biochemotherapy regimens

management focuses on patient education

include cisplatin, vinblastine, DTIC, interferon

and the most common side effects: flu-like

and IL-2. Response rates of 50% to 60%,

syndrome, fatigue, gastrointestinal effects,

complete remission rates of 10% to 20%

headache and hematological toxicity.

with a median survival of 11 to 1 2 months
were observed. Unfortunately patients

Chemotherapy agents used alone or in

experienced considerable toxicity with

combination have shown activity against

these regimens making it unrealistic for

melanoma; however, responses are generally

use in community-based hospitals.

of short duration. Laboratory and clinical
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Concurrent biochemotherapy regimens

The results of ongoing biochemotherapy

were introduced to reduce toxicity. An

clinical trials will be critical in determining

overall response rate of 64% was observed

the role of biochemotherapy in the

with a complete response rate of 21 %,

treatment of metastatic melanoma.

median survival of 12 months, and a

These types of regimens have allowed

2-year survival rate of 1 0%. The efficacy

the use of biochemotherapy to be given

of this regimen was comparable to the

safely in community-based settings. The

sequential biochemotherapy regimens,

adverse effects of biochemotherapy can

but it was less toxic.

be complicated, but experience has shown
that these side effects are reversible and
can be managed.

25

Vaccine Therapy

Jonathan Treisman, MD

Metastatic melanoma epitomizes cancer; a rapidly growing tumor that
can spread almost anywhere and which defies treatment efforts for most

Medical Consultants, Ltd.

patients. However, a few patients have spontaneous regression of their
tumors or respond to immune stimulation using interleukin-2, providing
a clue to the potential for immunologic treatment of this dreaded disease.
Lymphocytes (T-cells) have also been observed to accumulate in the tissue
of melanoma, and specific anti-tumor responses have been observed.
Directing the immune system may provide a path to curing this dreaded
disease. One process for directing the immune system uses vaccines and
has been a major focus of melanoma research and clinical trials for the
past JO years.

Vaccines have primarily been a tool for the control of infectious disease.
Vaccination against smallpox was the first and is probably the most well
known demonstration of the potential of vaccines to control disease.
Tumor vaccines try to take advantage of this understanding, and direct the
immune system against tumor cells and their various proteins. Vaccinating
against tumor cells has a number of special problems associated with it.
First, the cancer cells are part of the body, not a virus or other overtly
different organism. The body can view the cancer cells as part of itself and
become tolerant of the tumor cells. Secondly, the cancer cells are evasive
and may actually inhibit the immune system or mutate to evade the

‘4
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immune system. To destroy the cancer, the body needs to overcome its

J

natural desire for self-preservation of cells

used to treat the cells or added to the vaccine

that it views as self. Overcoming this

to enhance their immunogenicity. These have

tolerance is one of the goals of tumor

included infectious agents such as bacille

vaccines. The number of tumor reactive

Calmette-Guerin (BCG), Corynebacterium

cells must be adequate and increasing

parvum and viruses such as vaccinia and

the number of cancer-specific cells is another

vesicular stomatitis virus. The viruses are often

goal of vaccination.

used to make oncolysates where the cells are
destroyed by the virus and the strong viral

Some of the first efforts at vaccination utilized

antigens enhance the responses to the tumor

infectious agents in an effort to stimulate

antigens. Other tumor vaccines and adjuvants

an immune reaction at the tumor site. These

use immunogenic chemicals such as DNP,

could be administered systemically or as

KLH or miscellaneous materials such as

intra-tumoral injections. Although not

DETOX and alum.

successful, a number of the infectious agents
are still used in some form or another in

Knowledge of the immune system and tumor

more recent vaccine efforts.

immunology has been growing at a rapid
pace. One of the relatively recent changes is

Since the melanoma cells are the ultimate

our understanding of how T-cells recognize

target, it makes some sense that they should

antigens. In contrast to antibodies, which

be used as the vaccine. Tumor cell vaccines

recognize whole proteins and their associated

are prepared by removing cells from either the

shape, T-cells recognize only pieces of proteins,

patient (autologous) or from another patient

or peptides, which are attached to the HLA

(allogeneic) and processing them in some

molecule. This has led to the development

manner. These can be whole cells, lysates, or

of peptide vaccines in which only the short

extracts from the cells which are then injected

piece of protein is injected. The various

into the patient. These are generally used in

cytokines and co-stimulatory molecules that

conjunction with an adjuvant, an agent which

are involved in the response to antigens has

enhances the immune response that has been

also been growing and more recently, tumor
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vaccines have been generated by genetic

cell lysate from two allogeneic melanoma cell

modification of cells (transfection), including

lines combined with the proprietary adjuvant,

the insertion of various cytokines such as lL-4,

DETOX. CancerVax, a combination of three

GM-CSF, or co-stimulatory proteins such

allogeneic melanoma cell lines (with BCG

as B7.J and B7.2, or alternative HLA

as adjuvant) and autologous melanoma cells

molecules. These have been shown to increase

chemically modified with dinitrophenyl (DNP).

immunogenicity of the cells and clinical

These vaccines have produced some, albeit

studies are ongoing. Cytokines have also

low rates of objective responses in patients

been co-administered to try to induce an

with metastatic disease, sometimes with

immune reaction. As knowledge increases,

associated inflammatory responses at distant

so will the number of different vaccine

sites. Studies have even suggested that the

preparation methods.

vaccine improved disease-free survival of high
risk stage Ill patients and for some of the

Autologous tumor cell vaccines have the

vaccines improved survival was also suggested

advantage of presenting antigen in the

for patients with metastatic disease. So far,

context of the patient’s own HLA type and

however, the phase Ill trials have not shown

immunizing against antigens generated by

a clear benefit with one study of a vaccinia

patient- and tumor-specific gene mutations.

melanoma oncolysate showing no benefit

However, they must be prepared individually

in patients with stage Ill disease, and one

for each patient. Allogeneic tumor cells

trial showing no survival benefit to Melacine

provide a more reliable and uniform source of

over chemotherapy in patients with

antigen for preparation of vaccines, but target

metastatic disease.

only antigens that are shared between the cell
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lines in the vaccine and the patient’s tumor.

An alternative to the use of tumor cells in

Allogeneic tumor vaccines provide a source

vaccines has been to enrich the relevant and

of melanoma antigens as well as being

immune-activating components of tumor

immunogenic because of the response to

cells while excluding the irrelevant and

foreign HLA molecules. Melacine is a tumor

immune-suppressing substances that may

be present. Partially purified fractions of tumor

Cloned in large part by Dr. Thierry Boon and

antigens from allogeneic tumor cell lines

his colleagues, these antigens are encoded by

which are shed into the culture media are

genes with family names like MAGE, BAGE,

one such preparation and have shown

GAGE, RAGE, [AGE and CAMEL. NY-ESO-J

immune responses in mouse models. An

also falls into this group and is expressed in

advantage of this form of vaccine is the ability

a significant proportion of human melanoma

to use the same product for many patients.

cells as well as cancers of the breast, ovary,

Such an “off the shelf” type of product is

bladder, prostate and liver. A variety of other

more easily prepared and tested for eventual

antigens have been described, including

FDA approval. There has been an intense

antigens derived by the abnormal reading of

effort made to find the relevant tumor

the DNA (errors in reading frame), or mutated

antigens which can elicit an immune

antigen. It’s interesting that most of the

response. Dr. Steven Rosenberg at the NCI

tumor antigens are normal proteins. The

has pioneered this field by determining their

over-expression of these antigens in the

specificity of the tumor infiltrating lymphocytes

tumors makes them a target. However, normal

(TIL) which react against melanoma cell lines.

melanocytes are not always spared, and there

Many of the tumor antigens that have been

is actually an increased number of patients

identified, in the case of melanoma, are tissue

with vitiligo (loss of pigment in the skin).

differentiation antigens in melanocytes and

In fact the presence of vitiligo strongly

include gplOO (also known as HMB-45),

correlates with the response of the melanoma

MART-i /MelanA, tyrosinase, and tyrosinase

to treatment.

related protein-i /gp75 and tyrosinase-related
protein-2. Interestingly, these antigens are

Tumor antigens have been used in a variety

involved in the synthesis of melanin which

of ways to stimulate an immune reaction.

gives both melanocytes and deposits of

This includes the direct injection of DNA into

melanoma tumor their dark pigment. A

muscle (naked DNA vaccines), insertion into

second group of antigens are expressed by

any one of a number of viruses including

a variety of tumor histologies but are not

vaccinia and fowl-pox, injection of the short

expressed by normal tissues other than testis.

peptides which are the immune target or
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attempts to insert the genes into antigen-

The field of tumor vaccines is not new, but

presenting cells. Antigen-presenting cells are

still remains in its early stages. It is likely that

a group of cells which have the ability to

the massive knowledge that has been gained

process proteins and express them in

over the past 1 0 to 20 years, and the ongoing

the context of the Class I and Class II HLA

research into the biology of the tumor, the

molecules in association with the appropriate

immune system and their relationship will

co-stimulatory molecules. The best known

result in new prospects for a group of

of these is the dendritic cell, which can be

vaccines which are much more effective in

identified by its almost hair-like dendritic

the treatment of patients with melanoma.

projections. These cells can now be generated
using relatively straight-forward methods
and used to stimulate immune reactions.
They represent a target for the insertion of
the various tumor genes. The cells can also
be coated with the various tumor peptides
to ensure the peptides are presented in an
immunogenic fashion. The peptides have
also been mutated in an attempt to make
them more immunogenic and clinical studies
of these peptide vaccines and viruses are
ongoing. Responses have been observed in
some patients, but consistent responses are
still the vision rather than the reality.

Lymphatic Mapping and
Sentinel Lymph Node Excision
of

Percutaneous

Melanoma

i
James L. Mahoney,

Melanoma is a skin cancer that arises from the melanocyte cell which
produces the pigment melanin. Melanoma accounts for 4 to 5% of all skin

MD, FACS
Southeast Surgical, S.C.

malignancies and unlike other skin cancers, it frequently metastasizes
and melanoma can result in patient mortality. The depth of invasion of
the primary tumor is the most important prognostic factor and the depth
of invasion determines the metastatic potential of the tumor. Potential
sites of metastasis include the regional lymph nodes, the liver, lungs,
visceral organs, bones and the central nervous system.

Regional lymph node dissection in the treatment of melanoma has been
a controversial topic for many years. Removal of enlarged regional lymph
nodes, known as therapeutic lymph node dissection, has been generally
accepted in order to remove disease-bearing tissue. However, elective
lymph node dissection was controversial due to the surgical morbidity
and due to the lack of effective chemotherapy for metastatic melanoma.
This approach toward elective lymph node dissection changed when it
was established that Interferon Alpha-2b was effective chemotherapy in
high-risk patients with cutaneous melanoma. This resulted in a renewed
interest in identifying those patients with micrometastasis to regional
lymph nodes. Sentinel lymph node excision is a technique that accurately
identifies regional lymph node metastasis and spares a majority of patients
the potential morbidity of complete lymphadenectomy. The sentinel lymph
node is the first lymph node in a lymphatic basin to drain a particular
31

anatomic area of skin and it is the most

using a hand-held probe that detects

likely site of early metastasis from a primary

radioactivity. In addition to the

melanoma site. The identification and excision

lymphoscintigraphy, a second method is

of the sentinel lymph node can identify a

also utilized to visually confirm the sentinel

subset of patients with metastatic disease

node. just prior to making an incision,

who would benefit from a complete node

Lymphazurin blue dye is injected into the

dissection and would likely benefit from

skin surrounding the primary melanoma

additional therapy. The sentinel node

site. This blue dye is also taken up in the

accurately reflects the histology in the rest

lymphatics and is collected within the sentinel

of the nodal basin, and the likelihood of

node along with the radioactive substance.

metastatic tumor bypassing the sentinel node

A small incision is then made over the

to higher level nodes is less than 2%. Sentinel

localized lymph node and vital blue dye

lymph node excision is usually reserved for

is visualized in the lymphatics and sentinel

patients with a primary melanoma of greater

node. The radioactivity of the sentinel node

than 1 millimeter in thickness but less than

is then confirmed with a gamma probe

4 millimeters in thickness.

before and after excision of the node. It is
recommended that the lymphatic mapping

Technique

and sentinel lymph node excision be

Lymphatic mapping and sentinel lymph node

performed prior to wide local excision of

identification relies on two complementary

the melanoma in order not to disturb the

techniques of identifying the sentinel

normal lymphatic drainage pathways.

lymph node. On the day of surgery a
preoperative nuclear medicine study called

The success rate for identifying the sentinel

a lymphoscintigraphy is performed using

node is reported as high as 98% and is

Technetium 99 labeled sulfur colloid. This

certainly related to the individual surgeon’s

material is injected into the skin surrounding

experience with this technique. Metastatic

the site of primary melanoma and its

melanoma is found in up to 20% of sentinel

uptake in the lymphatics and sentinel node is

lymph nodes and it is recommended that

followed. This results in saturating the sentinel

those patients with metastatic disease

lymph node with radioactive material and

undergo a complete lymphadenectomy at

then this can be confirmed intraoperativety

a later time. The false/negative rate of this

procedure is an acceptably low 1 .5%

patients with metastatic disease to the
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it is unlikely that a patient with a negative

regional lymph node basin accurately

sentinel node will develop metastatic

and with a minimal amount of morbidity.

disease in the future. Most sentinel lymph

Those patients could then be treated

node procedures can be performed as

with further surgical therapy and may

an outpatient and usually requires a

be candidates for immunotherapy with

general anesthetic.

Interferon Alpha-2b. The technique of
sentinel lymph node excision is now being

In conclusion, it is clear that lymphatic

widely applied in the treatment of breast

mapping and sentinel lymph node excision

cancer and will likely be applied to the

has improved the care of patients with

treatment of numerous other malignancies

intermediate thickness melanoma. Sentinel

in the future.

lymph node excision can identify those

Pre-Operative Lymphoscintigraphy/Sentinel Lymph Node Biopsy
AHC

-

Metro

This graph shows the proportion of
patients who underwent pre-operative
Lymphoscintigraphy.
—

—

—

A total of 6 patients underwent
this procedure.
All 6 patients had sentinel lymph
node biopsy.
All of the patients had negative sentinel
lymph nodes.

100%
80%
not done
yes, unidirectional flow

60%
40%

• yes, multidirectional flow
• yes, flow unknown

—

20%

-

4
2

0%

—

Aurora
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Pathology
of Melanoma

Patrick W. Heintz, MD

Malignant melanoma (MM) is a malignancy composed of melanocytes,
cells that produce melanin and are present in the epidermis and dermis.

Great Lakes
Pathologists, S.C.

Histopathologic criteria for the diagnosis of melanoma incorporate both
architectural and cytologic features.

From an architectural standpoint, MM is characterized as a broad (typically,
but not always, greater than 6mm), asymmetric and poorly circumscribed
(i.e. the epidermal component trails oft as single cells rather than ending
abruptly as nests) proliferation of melanocytes. Unlike melanocytic nevi
(benign proliferations of melanocytes), melanocytes in MM tend to exhibit
extensive pagetoid spread, i.e. the melanocytes are distributed haphazardly
as small nests and single cells throughout all levels of the epidermis.
In addition, neither nests of melanocytes nor melanocytes themselves
exhibit maturation (that is, get smaller with increased depth of dermal
involvement) in MM as they do in melanocytic nevi.

Cytologically, malignant melanocytes have varying morphology, but
often will have abundant cytoplasm and enlarged, pleomorphic nuclei
with distinct nucleoli. However, cytologic characteristics in some types
of melanoma may be deceptively bland, whereas in certain variants
of melanocytic nevi, such as Spitz’s nevi, melanocytes have striking
cytologic atypia.

Malignant melanoma may be confined to

Superficial spreading melanoma is

the epidermis (melanoma in situ; always

characterized by extensive pagetoid spread

nontumorigenic/radial growth phase) or

of intraepidermal melanocytes, and is the

invasive; invasive melanoma can be further

most common type of melanoma, occurring

classified as nontumorigenic (“radial growth

most commonly on intermittently sun-exposed

phase”) or tumorigenic (“vertical growth

skin. Lentigo maligna melanoma exhibits,

phase”). An individual lesion may be

as the name implies, a lentiginous

categorized as tumorigenic if: 1) there is a

proliferation of atypical melanocytes along

dermal nest of melanocytes larger than the

the dermoepidermal junction, and early in

largest intraepidermal nest of melanocytes or

its evolution, may be quite subtle; this type

2) a dermal melanocyte in mitosis is identified.

of melanoma most frequently manifests on

Classical teaching is that nontumorigenic

chronically sun-exposed skin (especially the

melanoma lacks the capacity for metastasis.

face) of elderly individuals. Acral lentiginous

However, that concept is intuitively naive,

melanoma occurs on the palms and soles

as it relies upon recognition of histologic

and ungual and periungual regions, and

findings that may not be identified due

has histologic characteristics similar to those

to sampling error, a problem that plagues

of lentigo maligna melanoma; this is the

pathologic examination of all types of

predominant type of melanoma seen in

specimens. Therefore, any MM that exhibits

persons with dark skin. Desmoplastic

invasion should be considered to have

melanoma is a relatively uncommon vertical

metastatic potential. Therapeutic decisions

growth phase manifestation of primarily

are not dependent on nontumorigenic

lentigo maligna melanoma and acral

vs. tumorigenic classification.

lentiginous melanoma in which the dermal
melanocytes have a spindled nuclear

Several histologic subtypes of melanoma

morphology; this variant frequently exhibits

with characteristic clinical presentations

neurotropism. Nodular melanoma is

are recognized: 1) superficial spreading

characterized histologically by a purely

melanoma, 2) lentigo maligna melanoma,

vertical growth phase.

3) acral lentiginous melanoma, 4) desmoplastic
melanoma, and 5) nodular melanoma.
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In rendering a histopathologic diagnosis

Other negative prognostic indicators include

of malignant melanoma, the single most

ulceration (presumably because it leads to

important piece of information

—

underestimation of overall tumor thickness),

for both

prognostic purposes and to direct therapy

—

histologic evidence of regression and

is the Breslow tumor thickness, i.e. the

increased dermal mitotic activity. Favorable

measurement of the deepest malignant

prognostic indicators include location of the

melanocyte in the tumor from the overlying

MM on a hair-bearing portion of an extremity,

granular layer of the epidermis. Repeat studies

and tumor-infiltrating lymphocytes.

have confirmed that prognosis correlates
best with this histologic parameter, with

In summary, malignant melanoma is a

five year disease free survival inversely

potentially fatal cutaneous malignancy of

proportional to overall tumor thickness.

melanocytes that is diagnosed pathologically

Different histologic subtypes of melanoma,

based on careful examination of architectural

when of similar Breslow thickness, have the

and cytologic characteristics of an individual

same prognosis.

tumor. The most significant piece of
information to include in the pathology

Pathologists have also traditionally assigned

report is the Breslow tumor thickness of

a Clark’s level to MM: Level 1 connotes a

the melanoma. Assigning a histologic

melanoma confined to the epidermis

subtype is primarily of instructive/pedagogic

(melanoma in situ), Level 2 indicates papillary

value, as certain types of melanoma have

dermal invasion (“microinvasion”), Level 3

a characteristic clinical presentation, and

is invasion to the papillary/reticular dermal

knowledge of these patterns may lead to

interface, Level 4 indicates invasion of the

improved recognition. Clark’s levels are

reticular dermis, and Level 5 involves invasion

of historical significance, but impart little

into subcutaneous fat. Clark’s levels are

prognostic information.

primarily of historical significance, as this
classification introduces subjectivity into the
depth assessment of a MM, and Clark’s levels
are of far less therapeutic and prognostic
importance than the Breslow measurement.
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Clark’s Level of Invasion
AHC-Metro

The Clark’s Classification shows the anatomic level
of local invasion on histologic examination. Within
Aurora Health Care Metro, the greatest number
of patients presented with Clark’s Level II at 26%.
However, a significant number of patients presented
with Clark’s IV at 24%.
—

Level IV
Level Ill
170/4

LevelV

The levels involve the following tissues:
—

—

—

—

—

Level I:

N/A

Epidermis

Level II: Papillary Dermis

Level
26%

Level Ill: Reticular Dermal Interlace

Level I
20%

Level IV: Reticular Dermis
Level Vs Subcutaneous Tissue

Tumor Characteristics
AHC

-

Metro

Within Aurora Health Care’s Metro Region in 1 999, 6 patients or 14%
presented with an ulcerated melanoma, 3 patients (7%) had a clinically
amelanotic presentation, one patient (2%) had perineural invasion and
one patient (2%) had microsatellitosis.

Characteristic

Not Present

Present

N/A

Unknown

Angiolymphatic

40(87%)

0

5 (11%)

1 (2%)

40 (87%)

7(2%)

5(11%)

0

Ulceration

33 (73%)

6(74%)

5(11%)

1 (2%)

Clinically

37 (80%)

3 (7%)

5 (71 %)

1 (2%)

40 (87%)

7 (2%)

0

5 (7 1 %)

Invasion
Perineural
Invasion

Ame Ian oti c
Microsatellitosis
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Histologic Classification
AHC

—

Metro vs. NCDB (National Cancer Data Base)

60

57

50
Histologic Type of Melanoma

22

10

9

44

nodular Hutchinson’s superficial
spreading

pigmented

B AHC
B NCDB

43
57

I

1
I

13
7

9
10

31
22

Breslow’s Depth of Invasion
(vertical thickness in millimeters)

In-situ no size

9 cases

<.5 mm

3 cases

1 mm

1 7 cases

2 mm

6 cases

3mm

lcase

5 mm

1 case

10 mm

1 case

11 mm

1 case

30 mm

1 case

Unknown

1 case

Primary unknown

—

no size

5 cases

The Breslow stage more accurately predicts
subsequent behavior of malignant melanoma
lesions. Above are the findings in Aurora Health
Care Metro’s 1 999 PCE study.
—
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other
4
4

Histologic Classifications in AHC
—

Malignant Melanomas have varying
clinicopathologic cellular subtypes.

superficial
spreading
melanoma 31%

—

—

Metro
The graph shows the specific morphology of
the tumors seen in Aurora Health Care’s
Metro Region.

acral
lentiginous
melanoma 2%

melanoma in situ
.13%

melanoma in
Hutchinson’s
freckle 2%
melanoma in situ in
Hutchinson’s freckle 7%
amelanotic
melanoma
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Surgical

Paul Loewenstein, MD
Greater Milwaukee
Plastic Surgeons

Resection of
Malignant Melanoma

First the bad news: the incidence of melanoma in the United States
has increased dramatically over the last 20 years. Now the good news:
mortality from melanoma has only increased slightly over that same time
period.1 This means that more melanomas are being diagnosed and
treated at an early, curable stage. It is thus more important than ever
to select surgical treatment that is evidence based, since the application
of old treatment algorithms, requiring surgical margins of 3 cm or more,
do not improve long-term survival and are needlessly mutilating.
Since Dr. Alexander Breslow published his article relating tumor thickness to
prognosis of cutaneous melanoma in 1970, this method of microstaging
has become the standard for comparing outcomes and treatments for
meIanoma.2 What Dr. Breslow was really looking at was tumor volume,

I.

but this has been abbreviated to measurement of tumor thickness, which
is more reproducible. The other method of microstaging, the Clark level,
can be subject to interpretation, and can indicate a wide variety of tumor
burden when comparing for example the thin skin of the eyelid with the
thick skin of the back. Thus the single most important prognostic factor
is the Breslow thickness.

4d:1

The predicted five-year survival for melanomas

these were all in the narrow excision group

less than 0.76 mm thick is from 91% to 99%.

with a thickness of 1 mm or more.5

The corresponding 1 0-year survival is between
84% and 97%. For tumors 0.76-1 .5 mm
thick, five-year survival is roughly

Balch recently reported a study comparing
Since

2 cm versus 4 cm margins for 740 patients

prognosis and treatment are so closely linked

with 1 -4 mm melanomas. 1 0-year survival

with accurate microstaging, the method of

rates were not significantly different between

biopsy becomes very important. Whenever

the two groups.6 As far as depth is concerned,

possible, if suspecting melanoma, the entire

studies have failed to show a correlation

lesion should be excised. If the lesion is large,

between excision of muscle fascia and

or if it is impractical to perform a complete

improved disease-free interval or survival.1’8

excision, incisional biopsy is appropriate.4
Shave biopsy has virtually no place in the

Therefore, the current recommendations

diagnosis of melanoma.

for the surgical management of primary
cutaneous melanoma are as follows:

Once the diagnosis of melanoma has been
made, surgery is the accepted treatment.
The issue then becomes “how wide and

Tumor
Thickness

In situ

how deep?” The old dogma of 5 cm margins

Clinical Excision
Margin (cm)
0.5

Less than 2 mm*

has been pretty well laid to rest. In 1988,
Veronesi reported the results of a multicenter

Equal to or greater
than 2 mm*

2

WHO study comparing 1 cm margins with
3 cm or greater margins in patients with

*Some advocate, based on the three patients in

primary melanomas no greater than 2 mm.

the Veronesi study, that the cut-off for the 2 cm

Subsequent development of metastatic

margin be at tumors more than 1 mm in thickness.

disease, disease-free survival rates, and overall
survival rates were no different between the
two groups. Three out of the 612 patients
had local recurrence as a first relapse and

In no case, however, is it necessary to excise more
than a 2 cm margin or is it necessary to excise
the muscle fascia. A good overview of this topic
can be found in JAMA, Vol 285:1819-1821,
April 11, 2001.

Li_____
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Surgical Treatment
AHC

-

Metro vs. NCDB

This graph compares the surgical treatment between Aurora and the NCDB. The Aurora group
had more than twice as many patients who had no surgery (1 3% vs. 5%), fewer local tumor
excisions NOS (4% vs. 1 3%) and similar wide excision results (79% vs. 72%) reported through
the NCDB.

surgery nos

LI major amputation
I radical excision

Aurora

NCDB

LI
I
0%

42

20%

40%

60%

80%

wide excision, re-excision,
or minor amputation
biopsy followed by
gross excision
local tumor excision
local tumor destruction nos
no surgery

First Course Treatment
AHC

—

Metro vs. NCDB

This graph compares the first course treatment against the NCDB database
information. By far, both databases show that surgery alone is the most common
treatment (80% Aurora vs. 90% NCDB). At Aurora, Surgery plus BRM was more
than twice that of the NCDB (7% Aurora vs. 3% NCDB).

no RX
1otherRX

Aurora
j

(without surgery)

—

other RX
(with surgery)

NCDB

sugery +BRM

‘
0%

AHC

—

20%

60%

40%

sugery alone
700%

80%

Metro vs. NCDB Surgery Table

Of the surgical methods deployed most often to combat malignant
melanoma, wide excision/re-excision was performed definitively
78% of the time within AHC-Metro and 72% of the time nationally
(NCDB). Local tumor excision alone was performed only 4% of the
time in AHC-Metro vs. 1 3% of the time nationally.
Surgery

Aurora

NCDB

No Surgery

6 (13%)

Local Tumor Destruction

0

Local Tumor Excision

2 (4%)

3,144 (13%)

Biopsy followed by

1 (2%)

1,527 (6%)

36 (78%)

1 7,849 (72%)

1,257 (5%)
28 (.1 1 %)

gross excision
Wide excision, re-excision,
or minor amputation
Radical Excision

1 (2%)

Major Amputation

0

99 (.4%)

Surgery NOS

0

164 (.7%)

Total

46

595 (2%)

24,663
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The Genetics of
Hereditary Melanoma

Melissa Sopko, CGC

While the cause of all cases of melanoma can not be pinpointed to a
single risk factor, a significant feature is a positive family history. A strong

Genetics Counselor

familial predisposition increases the risk of developing melanoma over an
individual’s lifetime. It is estimated that between 5 to 1 0% of melanoma
cases are familial (i.e., inherited). Cancer genetic research has identified
a candidate gene located on chromosome 9p21 believed to play a role
in the predisposition of melanoma. This gene, called p1 6 (also known
as CDKN2A or INK4A or MTSJ) accounts for up to 40% of inherited
melanoma cases. p1 6 is a tumor suppressor gene involved in regulation
of cell growth. The job of p1 6 is to regulate cell proliferation by inhibiting
the CDK4 cell cycle protein kinase. Thus, alterations (mutations) in the
p1 6 gene disrupt its tumor suppressor function and lead to unregulated
cell growth.

In the United States, p1 6 mutations are likely responsible for 1000-2000
new melanoma cases each year. While the p1 6 gene accounts for the
majority of known genetic causes of inherited melanoma cases, other
genes may account for less than 1 % of hereditary melanoma cases.
A personal and family history of melanoma can also be associated with
other hereditary cancer syndromes including BRCA 2 mutations. It is
important for a healthcare provider to obtain a detailed family history
to accurately assess the risk of a p1 6 mutation causing the cases of
melanoma in a family.

An alteration in the p16 gene significantly

which is a first degree relative would suggest
hereditary melanoma (see graph). Additional

increases an individual’s risk of melanoma
and pancreatic cancer during their lifetime.

“red flags” are early age of onset of cancer,

Individuals that inherited p1 6 mutations

multiple primary tumors and family/personal

are at an increased risk of a diagnosis of

history of pancreatic cancer.

melanoma at an earlier age (34 years in
individuals positive for a p16 mutation
vs. 54 years in the general population),

Currently, there is commercial testing available
for p1 6 mutations. A genetic test for cancer

development of multiple primary melanomas,

susceptibility is not diagnostic. p1 6 testing

and development of pancreatic cancers.

does not reveal the presence or absence of
cancer, but whether an individual has an

For individuals with a mutation in the p1 6
gene, the risk of developing melanoma by age
80 is over 50-fold greater than the general
population and a lifetime risk of 1 7% to
development of pancreatic cancer is quoted.
There are many ways to try to reduce an
individual’s risk for the development of
melanoma. Interventions include minimizing

inherited susceptibility/predisposition to
cancer. Risks associated with genetic testing
are not physical risks but rather involve risks
associated with how one may feel or how
others, including family members, may react
after learning about a genetic test result. For
this reason, genetic counseling before and
after testing is recommended.

sun exposure and heightened surveillance
by frequent skin examinations. p1 6

p16 Mutations

genotype analysis of high-risk individuals
may influence the frequency of follow-up
(e.g., quarterly, semi-annually, annually,
etc.) with a dermatologist.

40%
0
C)

I-,

C)

C)
V
0
.4-’

(C

30%
20%

.4-’

There are “red flags” in personal and family
histories that suggest p1 6 involvement. At
present, no specific guidelines have been
developed for testing. However, at least two
or more affected family members, one of

E

10%
0%
1

2

3

4

5

# of family members with melanoma
Hayward, Curr Oncol Rep (2002) 2:300-306

Malignant Melanoma
AHC

—

Metro Region 1999 PatIent Care Evaluation Study

There were 46 patients who were diagnosed
and received their initial treatment in 1 999
at one of the Aurora Metro Region Hospitals
and met the ACoS recommended Patient
Care Evaluation Study (PCE) requirements.
—

—

—

WAMH
ASMC

39 of the patients were from St. Luke’s
Medical Center
5 of the patients were from West Allis
Memorial Hospital

SLMC

2 of the patients were from Aurora Sinai
Medical Center

85%

Stage at Diagnosis by Gender
AHC

-

Metro vs. NCDB

Aurora Health Care Metro saw more Stage I
patients than did the NCDB for both males
and females.

Relatively equal number of males and
females were seen both at AHC Metro and
the NCDB with Stage 0 and Stage Ill disease.

More females at both the local and national
level were seen for Stage IV disease.

The NCDB had many more unknown stages
than AHC Metro.

—

—

—

More males were seen at both the local
and national level for Stage II disease.

I

males AHC Metro
females AHC Metro
-

—

I

males NCDB
females NCDB

45%

0%
stage 0

46

stage I

stage II

stage Ill

stage IV unknown

Age by Sex
AHC

—

—

AHC

—

-

Metro vs. NCDB

Metro’s median age of diagnosis for men was 54.5; for women it was 64.

Compared to NCDB, AHC Metro saw a greater percentage of males younger than
40 years old (22% vs. 77 %) and females in the 60-69 range (30% vs. 1 5%).
—

35%
30%
25%
20%
15%
10%
5%
0%
males AHC

males NCDB

females AHC females NCDB

Malignant Melanoma Distribution by Sex
AHC

—

Metro vs. NCOB

The sex distribution of patients seen in Aurora’s Metro Region is even at
50% male and 50% female. This is compared to data from the National
Cancer Data Base (NCDB). The NCDB database contains 24,663 melanoma
cases diagnosed or treated in 1999 from 1,402 hospitals. The NCDB shows
slightly more males (57%) and less females at 43%.

60%
50%
40%
30%
20%

1

10%
0%
AHC

• male
I female

NCDB
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Melanoma 1993-1994
5 Year Survival
AHC

—

Metro

The observed survival rate was calculated for the melanoma cases from 1 993-1 994 and
compared to survival statistics from the NCDB. There were 67 cases in the Aurora data
base. The breakdown by stage is as follows:
—

—

Stage 0: 8 cases
Stage 2: 1 7 cases

—

—

Stage 1: 36 cases
Stage 3: 6 cases

There were no stage 4 cases. At the end of 5 years, the observed survival rate for Stage 0
was 1 00%, Stage 1: 76%, Stage 2: 80%, Stage 3: 50%.
With the exception of the Stage 7 cases, a greater percent of the Aurora patients were alive
at the end of 5 years.

B

100%

80%

\

60%

I

stage 0
stage 7
stage 2
stage 3
stage 4

40%
year 1

year2

year 3

year 4

year 5

Malignant Melanoma by Race and Primary Site
AHC

-

Metro

All of the patients
were caucasian.
40 of the patients
presented with a
melanoma of the skin.
One person presented
with melanoma of
the vulva.
5 patients presented
with a metastatic lesion
and the primary tumor
was never found.
By convention, these
patients are coded
to Skin NOS (Not
Otherwise Specified).
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vulva
skin nos
2%\
11%

ear2/o

other unspec.
parts face 17%

—

lower limb!
shoulder
22%

scalp and
neck 7%

—

‘—skin of
trunk 22%
upper limb!
shoulder 17%

-

Melanoma 1993-1994
5 Year Survival
NCDB

The NCDB database contains 26,7 58 melanoma cases from 1 993-7 994. The breakdown
by stage is as follows:
—

—

Stage 0:4,791 cases

—

Stage 2: 6,509 cases

—

Stage 1: 17,794 cases

—

Stage 4: 7,354 cases

Stage 3: 1,770 cases

At the end of 5 years the survival by stage was: Stage 0: 86%, Stage 1: 85%, Stage 2: 65%,
Stage 3: 41 %, Stage 4: 72%.

100%
80%
60%

• stage 0
stage 1

40%

S stage 2
• stage 3

20%

S

stage 4

5

stage 0

0%
year 1

year2

year 3

year 4

year 5

AjCC Stage at Diagnosis
AHC

-

Metro vs. NCDB

The graph to the right illustrates
the stage at diagnosis for males
and females combined. The data
is compared to the NCDB data.
The NCDB had slightly fewer
melanomas in the Stage I category
(37% vs. 41% AHC) and the Stage
IV category (4% vs. 1 3% AHC)
and had more with an unknown
stage (17% vs. 1%AHC).

1.0
0.09

0.8

—

0.11

stage I
stage II
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—
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—

stage Ill
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S
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0
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Regional Activities
in Aurora’s Metro Region]

Clinical Research Department
Oncology Report
-:3

Carol Tutino, ESN, CCRC
Manager,

The Clinical Research Department continues to support all areas of
oncology with new clinical trials. This includes medical and surgical
oncology, radiation therapy, bone marrow transplant and immunotherapy.

Clinical Research

The number of clinical trials that opened in 2001 at Aurora Health Care
more than doubled and we saw a 50 percent increase in patient enrollment
over the 2000 figures. More than half of the Clinical Research Department
staff was involved with the coordination of oncology studies during this
same time period.

One of the more exciting studies that opened in 2001 was one that was
associated with developing a screening tool for the early detection of
breast cancer using saliva. Women donated saliva and blood samples and
completed a short questionnaire at the time of their yearly mammogram.
Another exciting study that continues to enroll subjects involves plasma
pheresis and a prostate vaccine for men diagnosed with prostate cancer.
In addition to the many cooperative group studies that the department
supports, these and other clinical trials have made it possible for all cancer
patients to actively participate in a research study if they so desire. This
has allowed the oncologists at Aurora Health Care the opportunity to offer
their patients optional treatments in addition to standard of care.

LL_

Vince Lombardi
Cancer Clinics

William J. Laffey, MBA
Cancer Services
Regional Director

Care was
The first Vince Lombardi Cancer Clinic within Aurora Health
1 989. Named
established at St. Luke’s Medical Center in Milwaukee in
life to cancer, the
after the legendary Green Bay Packers coach who lost his
level of passion
clinic was founded to serve patients and families with the
rdi teams. Since
and quest for excellence that were synonymous for Lomba
original Vince
then, the services, resources and philosophy of care of the
nts beyond
Lombardi Cancer Clinic have been extended to benefit patie
Lombardi Cancer
the greater Milwaukee area. Currently, there are ten Vince
ns:
Clinics operating in eastern Wisconsin at the following locatio
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• St. Luke’s Medical Center

Milwaukee

• St. Luke’s South Shore

Cudahy

• Aurora Health Center

Slinger

• Regional Cancer Center

West Bend

• Aurora Lakeland Medical Center

Elkhorn

• Regional Cancer Center

Sheboygan

• Manitowoc Clinic

Manitowoc

• Aurora Medical Center

Kenosha

• Aurora Sinai Medical Center

Milwaukee

• Aurora BayCare Medical Center

Green Bay

Each Vince Lombardi Cancer Clinic offers:

Registered nurses from all sites developed

• Board-certified medical oncologists

a binder for patients containing all the

directly connected to the resources

information they need as they journey

of St. Luke’s Regional Cancer Center

through the various stages of cancer care

• Registered nurses specializing in
oncology who provide chemotherapy

from initial diagnosis to treatment and
then post-treatment.

and supportive care services in a
comfortable setting
• Comprehensive diagnostic and
treatment options

The community link to all the Vince
Lombardi Cancer Clinics is a toll-free
hotline available 24 hours a day

• Access to the latest treatment protocols

(800-252-2990). Hotline staff put callers

• Access to clinical nurse specialists,

in touch with accurate answers to a

dieticians, counselors, social workers

variety of cancer questions ranging from

and chaplains, as well as home care,

prevention and detection concerns to how

if needed

to access the latest treatments, research

• Vince Lombardi Resource Library and

protocols and support groups.

a CancerHelpTM computer for patient
research and information
• Community outreach programs and
support groups

The Vince Lombardi Cancer Clinics
continually work together to improve
service to patients and their families.
A recently completed project had the
goal of improving patient and family
knowledge and understanding of

‘1

chemotherapy treatment and side effects.
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Comm unity
Outreach Activities

Marija Weidman, RN, MSN

Our community outreach activities continue to expand and evolve around
the specific needs and concerns of the communities we serve. In the past

Business and
Market Development

year, our concerted efforts to broaden and customize cancer education
programs and services have led to innovative partnerships and initiatives
with businesses and organizations outside of the traditional health care
model. We’ve become increasingly creative and much more mobile.
We’re spreading the word about cancer risk awareness, prevention and
early detection to people at work, school, church and even at the mall.
By offering more than the typical, we’re reaching more people, more
effectively. Here are some recent highlights:

Always mindful that women are typically the “health care directors” of
their families, we were pleased to incorporate men’s health issues such as
prostate cancer into the Second Annual Celebration of Women’s Health
at Mayfair Mall on Saturday, September 21. This partnership between the
Aurora Women’s Pavilion and Wisconsin Woman Magazine was a daylong
event attended by thousands of individuals. Activities included consumer
education presentations by physicians and health experts, demonstrations,
health screenings and displays about key programs within Aurora
Health Care.

As a result of a new partnership, the Vince

Another community partnership helped target

Lombardi Resource Library will soon be

our approach to increasing cancer awareness

a featured service at Gilda’s Club, a free,

at the Third Annual Men’s Health Conference

non-residential clubhouse now under

in September 2002. By joining forces with

construction at 4050 N. Oakland Avenue

Church of God in Christ, Inc. (COGIC), we

in Shorewood. This special facility, scheduled

were able to educate a large population of

to open in 2003, will offer a warm and

African American men who are at higher risk

welcoming place for men, women and

for developing prostate cancer. Our efforts

children to share hopes, fears, wisdom and

included funding for free screenings through

information as they learn how to live with

the National Prostate Cancer Coalition’s Mobile

cancer. Gilda’s Club is part of a national

Prostate Screening Van at the conference site.

non-profit organization created by actor
Gene Wilder, a Milwaukee native married

During National Melanoma Month in May, we

to the late comedienne Gilda Radner, who

were proud to bring in Dr. Kelly McMasters,

died of ovarian cancer. Through the Vince

head of the Sunbelt Melanoma Trial, to speak

Lombardi Resource Library, visitors to the

to physicians in Aurora’s South and Metro

local clubhouse will be able to access

Regions about the latest approaches to

current cancer information online, check

management of melanoma.

out video and audio tapes, and take home
brochures, fact sheets and other printed

Our presence at the Vince Lombardi Cancer

material. The library will be unique in that

Center “Run for Daylight” in June allowed us

it will include all of the resources traditionally

to reach hundreds of runners, walkers and

available at Vince Lombardi Resource Libraries

their families with information about early

in other locations, as well as resources

detection and our services Participants also

from all cancer-serving organizations in

joined us in the celebration of National

southeastern Wisconsin.

Cancer Survivor’s Day at Menomonee Falls
High School.
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As part of Aurora’s Breast Cancer Awareness

In addition to our highlights of the year, we

Initiative, we were proud to support the Girl

continued to educate people across eastern

Scouts of Greater Milwaukee to teach young

Wisconsin through established activities

girls (and their moms) about the importance

such as the Vince Lombardi Cancer Hotline,

of early detection. Our involvement helped

community education lectures at local hospitals

the girls earn their Breast Cancer Awareness

and clinics, and cancer screenings and health

patch. This effort will be repeated in the

information programs for employees through

coming year.

partnerships with area businesses.

Cancer
Support Groups

r

J

Barbara K. Clinkenbeard,
MS, NP
Vince Lombardi Cancer
Counseling Center

Cancer can take over a person’s whole life. It can affect how they feel,
their relationships with family and friends, even plans for their future.
Our mission at the Vince Lombardi Cancer Counseling Center is to
be the best, most comprehensive mental health care center for cancer
patients and their families.

Many people find that psychological support during this difficult time
is helpful. Through the Vince Lombardi Cancer Counseling Center,
patients and their loved ones can find the support system they need to
cope with the emotional aspects of cancer. Our comprehensive services
include counseling sessions in an individual, family or group setting,
complementary therapies, educational and support materials, psychological
testing and assistance with fatigue, pain, insomnia, appetite disturbances,
depression and anxiety.

The medical director at the Center is jeffrey Knajdl, MD, a psychiatrist
whose experience includes psycho-oncology

—

a medical specialty focusing

on the psychiatric issues faced by people with cancer. Dr. Knajdl is
responsible for developing a comprehensive delivery system of psychosocial
care for cancer patients and their families. Under his direction, all of us
at the Center work to guide individuals and their loved ones through
the emotional challenges that often accompany a serious illness.

One of our program highlights is our

An array of programs is offered to complement

Individual, Family and Group Counseling

our services, each designed to help individuals

program. Through counseling, we look for

while living with a serious illness. These

the psychological and medical causes of an

programs include Support Groups, Nutrition

emotional problem brought on by a medical

Counseling, Spiritual Care, Massage Therapy,

condition such as cancer. Psychologists are

Pet Therapy and Expressive Therapy. We

consulted frequently to provide individual,

also offer unique programs such as Kids’

couples and family therapy.

Connection

—

to help children better understand

the causes, symptoms and treatments of
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and Refocusing on Hope

a support

Cancer and the treatments designed to fight

cancer

it can also sometimes cause unpleasant and

group for people with a primary brain tumor.

distressing symptoms. Some of them are

The massage therapists at the Vince Lombardi

physical (fatigue, pain, appetite disturbance)

Cancer Clinic have advanced training

while others are emotional (anxiety, fear,

specifically designed to safely provide massage

hopelessness, depression). We work to explore

therapy for cancer patients. They have

options for treating these complications.

completed this scientifically based education

Often counseling and relaxation tips are

through Integrative Medicine Service at

effective, but when necessary we prescribe

Memorial Sloan-Kettering Cancer Center

medicines to help reduce the physical and

in New York. In addition to physical and

emotional distress. Finding the right balance

emotional support, patients and their loved

between the options is our goal. The Cancer

ones often find the spiritual care we provide

Counseling staff also provides psychological

offers another dimension of treatment.

testing to evaluate cognitive function in

Chaplains are always available to see patients

determining whether assistance is needed

who may be experiencing isolation, grief,

before resuming everyday activities like

guilt, hopelessness, concerns about death, loss

work, school and driving.

of faith or who have specific ritual needs.

—

—

Support Groups

Us Too! The Prostate Cancer

A variety of support groups are offered

Support Group

to provide education, the sharing of

Men who have experienced prostate

experiences and inspiration for people

cancer are invited to attend with family

whose lives have been touched by cancer.

and friends.

Newly Diagnosed With Breast Cancer

This group is for people who have just
been told they have cancer, and their
loved ones.
Breast Friends

Care for the Caregiver

A supportive environment where
caregivers can discuss concerns and
share ideas.
Kids’ Connection

This group is dedicated to women who

To help children ages 5 through 1 8 cope

have been diagnosed with breast cancer,

when a parent or loved one has cancer.

their families and friends.

Positive People

Your Caring Connection

For patients living with cancer, their

Patients affected by cancer and their
families or loved ones are encouraged
to attend this group.
Make Today Count

A program offered in cooperation with
the American Cancer Society, this group
is designed for people with cancer or other

family, and friends. This group offers
an opportunity to share problems
and concerns.
Refocusing On Hope

—

Brain Tumor Support Group

For people who have been diagnosed with
brain tumors, their families and friends.

life-threatening illnesses and their families.
For more information about these
support groups, call 1 -800-252-2990.
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Tumor Boards and
Specialty Case Conferences

are
Regularly scheduled tumor boards and specialty case conferences
te
offered to provide an opportunity for health care providers to evalua
patients.
and discuss multidisciplinary treatment plans for newly diagnosed
clinical
The most current advances in diagnostic techniques, staging and
to
trial information are included in the discussion, which overall leads
improved quality of care for patients.
The consultative forums listed to the tight allow any physician the
never
opportunity to present cases of special interest. Patient identity is
revealed to the participants of the conferences in order to protect
hosted
confidentiality and privacy. In 2001, the Metro Region Hospital’s
over 200 scheduled conferences and presented over 600 prospective
cancer cases, including information on over 30 anatomical sites.
Aurora Health Care provides category 1 credit towards the AMA
hours
Physician’s Recognition Award for each physician claiming those
serial
of credit that he/she spends participating in the conferences. The
ers
conferences listed to the right are open to all health care provid
of Aurora Health Care.

Conference

Location

Room

Frequency

Day

Time

Tumor Board

SLMC

Health Science

Weekly

Fridays

12:00

Weekly

Fridays

1 2:00

Weekly

Fridays

1 2:00

Monthly

Fourth

1 2:00

-

1:00pm

Classroom #3
Tumor Board

ASMC

Rapkin

-

1 :OOpm

Auditorium
Tumor Board

WAMH

Conference

-

1 :OOpm

Room A/B
Tumor Board

AMC

—

H

Third Floor
Conference Room

Gl Case

SLMC

Health Science

Conference
GI Case

ASMC

Tuesday
Weekly

Tuesday

7:00

Weekly

Monday

1 2:00

Weekly

Tuesday

12:00

Weekly

Tuesday

7:30

Weekly

Wednesday

7:30

2nd Floor Surgical

Every Other

Thursday

7:30

Conference Room

Week

Lavender/Sage

Weekly

Monday

7:30

Rapkin

-

8:00am

-

1 :OOpm

Auditorium
SLMC

Health Science

Conference
Radiosurgery/

1 :OOpm

Classroom #3

Conference
Endocrine Case

-

-

1:00pm

Classroom #3
SLMC

DVI

Neurosurgery

-

Reading

-

8:30am

Room

Conference
Breast

SLMC

Health Science

Conference
Breast

9:00am

Classroom #3
ASMC

Conference
Breast

-

AWP

Conference
Aurora Medical Center Hartford (AHC
1032 East Sumner Street
Hartford, WI 53027
Aurora Sinai Medical Center (ASMC)
945 North 12th Street
Milwaukee, WI 53233

-

-

9:00am

9:00am

Conference Room

—

H)

Aurora Women’s Pavilion (AWP)
8901 West Lincoln Avenue
West Allis, WI 53227
St. Luke’s Medical Center (SLMC)
2900 West Oklahoma Avenue
Milwaukee, WI 53215

West Allis Memorial Hospital (WAMH)
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This report excludes carcinoma in situ cases of the cervix and basal cell carcinomas of the skin.
A=Analytical, N/A=Non-Analytical
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Cancer Data Statistics
Incidence of New Cancer Cases 1995-2001
3,442 new cancer cases were seen in the Metro Region in 2001. The number of new cancer
cases has increased at all the facilities from the previous year of 2000. Site numbers include
St. Luke’s Medical Center 2,268 (includes SLSS) with 89% classified as analytical (diagnosed
and or treated within the first course of treatment), Aurora Sinai Medical Center, 361
with 90% analytic, West Allis Memorial Hospital 691 with 90% analytic and Aurora Medical
Center Hartford with 1 22 cases of which 64% are analytic. Aurora Medical Center’s
non-analytical case load is a bit higher than usual due to the collection of Vince Lombardi
Cancer Clinic cases (class of case 6).
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Race by Hospital
Review of all (3,442) new cases in 2001 shows the population served at
St. Luke’s Medical Center and West Allis Memorial Hospital is predominantly
white with 97% and 99% respectively. By contrast the central city location
of Aurora Sinai Medical Center serves a more diverse population with the
majority being of African American (49%) descent, with 1% American Indian,
1% Asian and 1% Other.
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New Cases Breakdown
Analytical vs. Non-Analytical (First Course vs. Subsequent Rx)

The analytical percentages at each facility are as follows: St. Luke’s Medical Center 89%
classified as analytical (diagnosed and or treated within the first course of treatment),
Aurora Sinai Medical Center, 90% analytic, West Allis Memorial Hospital 89% analytic
and Aurora Medical Center Hartford with 64% analytic.
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Sex by Facility
Males vs. Females

More women than men were seen at all Metro region sites in 2001. In total, 1,771
or 56% were women with 1,366 or 44% being male. According to the estimated
new cancer cases for 2002 based on the incidence rates from the NCI SEER
program the sex ratio is even (50/50). The State of Wisconsin’s Cancer Incidence
and Mortality Report for 1 999 indicates that cancer rates were higher for men
than women for all primary site groups. The annual cancer incidence rate was
423 per 1 00,000 population for males and 339 per 1 00,000 population for
females. Of the total number of cases the incidence was split 50/50.
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Age at Diagnosis within Metro
When comparing age differences among the Metro Region Hospitals we find younger
patients being diagnosed at Aurora Sinai Medical Center with a mean age of 65.
At St. Luke’s Medical Center and West Allis Memorial Hospital the mean age is 75 with
St. Luke’s Medical Center showing a larger portion of the patients being diagnosed younger
than the mean, whereas at West Allis Memorial Hospital, the patients are being diagnosed
at ages slightly higher than the mean. One of the key findings of the Wisconsin Cancer
Incidence and Mortality report is that 60% of the newly diagnosed cases in 7999 were
age 65 and older.
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AJCC 5th Edition Stage of Disease at Diagnosis
AJCC Stage at Diagnosis

When looking at the stage of disease at presentation for the analytical patients within Aurora Health
Care’s Metro Region, the majority of cases presented with Stage I disease (22%-24%) or Stage II disease
(27 %-25%). Carcinoma in-situ or Stage 0 disease was present between 2% and 9% of the time, Stage Ill
disease between 77%-i 4% of the time and Stage IV between 74%-i 7%. The percentage of cases that
were unknown or that did not have a staging schema constituted between 1 6%-20%.
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Comparison Top 5 Sites
When comparing the top five sites in order of decreasing frequency in the Metro region to the
incidence of cancer cases reported by the state and the National Cancer Date Ease (NCDB), it is
noted that the Metro region sees a higher percentage of breast cancer cases (20%), fewer prostate
cases (10%) and a relatively equal number of lung (14%), colorectal (11%) and bladder cases (4%).
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Patty Abella, RN, MSN Medical Oncology
Betty Amuzu, MD OB/GYN
Saleem Bahktiar, MD General Surgery

•

Diane Beier, CICSW Social Services
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Nancy Briggs, RN, OCN Research
Jerome Buboltz, MD Internal Medicine

John Naida, MD Radiation Oncology
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William Donegan, MD Chairman, Surgery
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Mark Gennis, MD Internal Medicine
•

Ronald Grossman, MD Radiology
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Timothy Heilizer, MD Surgery
Jana Hitchcock, MSW Social Services
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Margery Howard, MD Medical Oncology
Rakesh Jagetia, MD Chairman Radiation Oncology
Julie Jensen, RN, MSN, NP Nursing
Barbara johnson-Farmer, RN Women’s Health

C

•

Pat Kadlec, RN Outpatient Nursing
Mary Kannenberg, RHIA Quality Management/CIS
John Kelly, MD Otolaryngology
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Kenneth Klein, MD Radiation Oncology
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Daniel Kopesky, MD OB/GYN
William Laffey, MBA Reg Director Cancer Services
Margaret Lange, RN Outpatient Oncology
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Ann LeFever, PhD Immunotherapy
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David Lewis, MD General Surgery
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Janet Lotegeluaki, RN, OCN-CNS
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Roger Pellman, MD Radiology
Joseph Pfotenhauer, MD Internal Medicine
John Pickeral, MD Pathology
Mitchell Pincus, MD Radiation Oncology
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Lisa Robinson, RHIA, CTR Clinical Data Registries
Mary Runge, RN, MBA VNA Hospice Services
Lori Sadowski, RN Inpatient Nursing
Suzanne Schmidt, RN Breast Coordinator
Mark Schwartz, Administration
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Moni Stein, MD Interventional Radiology
Rodolfo Suaverdez, MD Family Practice
Moniq ue Swiecichowski, RN Research

Robert Taylor, MD Medical Oncology
Donna Theesfeld, RN Quality Management
Mary TiIIe MD Pain Management
Judy Tjoe, MD Surgery
Sue Toth, RN Breast Care Coordinator
Allen Torkelson, MD Medical Oncology
Jonathan Treisman, MD Medical Oncology
Carol Tutino, RN CCRC Research
Kerry Twite, RN, OCN-CNS VLCC
Vicki VoIp, RN, MSN Quality Management
Matt Waddell, RN 8GHJK
Deborah Wham, CNC Genetic Counselor
Marija Weidman, RN, MSN Bus. & Market Dev.
Mark Wenzel, MD Radiology
Phil Whitton, RH Manager Radiation Oncology
Walter Wong, MD Radiation Oncology
JoAnna Yeh, PharmD Pharmacy
Sol Yoder, PharmD Oncology Pharmacy
George Yu, MD Pathology
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Melissa Sopko, CNC Genetic Counselor
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Jane Seymour, RHIT, CTR Cancer Registrar
Gary Shapiro, MD Medical Oncology

•

Robert Hall, MD Pathology
John P. Hanson, MD Medical Oncology
Ronald Hart, MD Medical Oncology
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Uday Gupte, MD Gastroenterology
Sheri Hackbarth, RHIA Cancer Registry
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Becky Pogacar, RN, MSN Nursing
Kim Reed, RN Inpatient Nursing
Diane Reif, RN Patient Care Manager
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Donald Feinsilver, MD Psychiatry
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William Pao, MD Radiation Oncology
Nileshkumar Patel, MD Pain Management
Jorge Pellegrini, MD Pathology
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Cindy Ganzel, RN, RHIT Cancer Registry
Daniel Geenen, MD Gastroenterology
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Sharon Paulson SLSS Oncology
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Jan Dietrich, RN VNA Hospice Services
Ajit Divgi, MD Medical Oncology

Marie Golanowski, Vice President/CNE
Perry Gould, MD Radiation Oncology
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Mahmood Mirhoseini, MD Cardiothoracic Surgery

Chris Cullen, RN, MBA Quality Management
Michael Dawson, MD Internal Medicine
Mark Decker, MD OB/GYN
Jeffrey Derus, MD Chairman, Urology

Mary Mavraganis, MS Social Services
Wendy Mikkelson, MD Breast Surgery
Tracy Miller Cancer Registry
Sara Moldenhauer, RN, CNS 8GHJK
David Munoz, MD Family Practice

Brian Butler, MD Urology
David Chen, MD Internal Medicine
Jacque Coons, RRT Quality Management
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Pamela Maier, RN Inpatient Nursing
Rev. Marcia Marino Pastoral Care
Linda Martin, BSW Social Services
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Linda Barrows, MD Physical Med & Rehab
Kenneth Bastin, MD Radiation Oncology
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Key: CChairperson L=ACoS Liaison B=Both

ëAurora Health Care®
www.AuroraHeatthCare.org

Aurora Medical Center
1 032 East Sumner Street
Hartford, WI 53027
Aurora Sinai Medical Center
945 North 1 2th Street
Milwaukee, WI 53233
St. Luke’s Medical Center
2900 West Oklahoma Avenue
Milwaukee, WI 53215
St. Luke’s South Shore*
5900 South Lake Drive
Cudahy, WI 53110
West Allis Memorial Hospital
8901 West Lincoln Avenue
West Allis, WI 53227

*Included in St. Luke’s Medical Center Data
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